ERX Pharmaceuticals Announces Appointment of Chief Medical Officer Barbara Troupin, MD, MBA and Chief Financial Offer Jonathan Lieber, MBA
CAMBRIDGE, Mass., May 1, 2019 — ERX Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative treatments for obesity and related diseases, announced the expansion of its executive leadership team with the appointments of Barbara Troupin, MD, MBA as Chief Medical Officer and Jonathan Lieber, MBA as Chief Financial Officer.
Dr. Troupin most recently served as Chief Medical Officer and Vice President of Clinical Development & Regulatory Affairs at Aquinox Pharmaceuticals and Senior Vice President of Clinical Development and Chief Medical Officer at Apricus Biosciences. She also held senior roles at VIVUS in clinical development and medical affairs, where she played an instrumental role in the development and approval of Qsymia for the treatment of obesity.
“Barbara has a strategic understanding of the development and regulatory landscape in obesity, the relationship between obesity and the progression to metabolic disease, and the challenges that clinicians face due to a lack of effective therapeutic options in this space,” said Teo Uysal, MBA, President and CEO of ERX Pharmaceuticals. “In addition to her expertise in this therapeutic area, we will benefit greatly from Barbara’s experience building clinical development, regulatory affairs, and medical affairs functions at clinical-stage companies as they progress through the development pathway. Barbara is well known and well respected by key clinicians and thought leaders in obesity and metabolic disease, which also will be invaluable to our success as we advance our programs through clinical development.”
Dr. Troupin completed her medical degree at the University of Pennsylvania, her MBA at The Wharton School of Business, and her Family Medicine Residency in San Diego.
Mr. Lieber brings more than 20 years of experience in financial and executive management at emerging growth life sciences companies and in investment banking. He has held a series of Chief Financial Officer roles, including most recently at Histogenics Corporation, Metamark Genetics Inc., Repligen Corporation, Xcellerex Inc., and Altus Pharmaceuticals. As a CFO he has raised over $300 million of capital in public and private offerings and led multiple strategic processes including the sale of Xcellerex to GE Healthcare.
“Jon is a veteran financial executive who has overseen the growth and development of a number of early stage life sciences companies such as ours,” said Uysal. “With Jon’s strong track record in raising and optimizing capital, we will be well positioned to manage the next phase of our growth.”
In conjunction with his role at ERX Pharmaceuticals, Mr. Lieber serves as a Managing Director at Danforth Advisors, a company providing integrated and scalable finance and accounting solutions to healthcare companies. He completed his BS in business administration and finance at Boston University and his MBA from New York University Stern School of Business.
“At ERX, we are focused on developing a novel treatment for obesity using leptin sensitization, with a goal of addressing a major unmet need for a disease impacting approximately 40% of the US population today,” said Uysal. “There is significant market potential for safe, well-tolerated, easily-administered and accessible obesity therapies that deliver the level of efficacy that is needed to achieve the goals of both patients and clinicians. We are thrilled to grow our executive team with experienced leaders who are well poised to help us succeed in this challenging but extremely important therapeutic area.”
About ERX Pharmaceuticals
ERX Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative treatments for obesity and related diseases. ERX’s research program is based on a new understanding of the role of the hormone leptin in appetite control and energy expenditure, and the potential for leptin sensitizers to overcome the state of leptin resistance in obesity and related diseases. ERX’s lead drug candidate, ERX-1000, is an orally-delivered first-in-class leptin sensitizer that recently completed a first-in-human Phase 1, double-blind, placebo-controlled, single and multiple dose study in healthy obese and non-obese subjects. For more information about ERX Pharmaceuticals, its research focus on leptin sensitization, and its pipeline, visit www.ERXpharmaceuticals.com.